ACUVUE® OASYS 1-Day with HydraLuxe® Technology for ASTIGMATISM

Box of ACUVUE® OASYS 1-Day for ASTIGMATISM
ACUVUE® OASYS 1-Day for ASTIGMATISM, a daily contact lens with EYELID STABILISED DESIGN to help provide clear, stable vision throughout the day, even with eye or head movements.1
Box of ACUVUE® OASYS 1-Day for ASTIGMATISM
ACUVUE® OASYS 1-Day for ASTIGMATISM, a daily contact lens with EYELID STABILISED DESIGN to help provide clear, stable vision throughout the day, even with eye or head movements.1

Benefits to share with your patients

Clear and stable vision6

ACUVUE® Contact Lenses for ASTIGMATISM with EYELID STABILISED DESIGN are designed to realign naturally with every blink and have been shown to help provide clear and stable vision throughout the day, even with extensive head and eye movements.6

Comfortable experience all day, every day2,4

Exceptional performance$7. Gentle on the eye for a comfortable experience all day, every day2,4

Built-in UV protection†8

Maintains the highest level of UV-A and UV-B protection to block at least 90% UVA and 99% UVB†8

30-day pack

Available in 30 day pack for daily wear

Lens specifications

TitleDescription

Lens Material

Senofilcon A

Technology

Polyvinyl pyrrolidone

(PVP) using HydraLuxe® Technology

EYELID STABILISED

DESIGN

Water Content

38%

Class 1 UV blocker3†

90% of UVA rays, 99% UVB rays

Center thickness at -3.00D

0.080mm

Base Curve

8.5mm

Diameter

14.3mm

Power Range

Plano to -6.00D (0.25D steps):

-0.75DC, -1.25DC, -1.75DC

Axes 10–180 (10° steps)

-2.25DC axes 70–110 and 20–160 (10° steps)

-6.50D to -9.00D (0.50D steps):

-0.75DC, -1.25DC, -1.75DC

Axes 70–110 and 20–160 (10° steps)

+0.25D to +4.00D (0.25D steps):

-0.75DC, -1.25DC, -1.75DC

Axes 70–110 and 20–160 (10° steps)

Visibility Tint

Yes

Pack size

30 lens pack

A closer look at what sets these apart

More key benefits

  • The components within ACUVUE® OASYS 1-Day for ASTIGMATISM are uniquely combined to create a patented, first-of-its-kind material based on HydraLuxe® Technology that uses the power of a patient's own tears to help deliver exceptional comfort.2*
  • Featuring EYELID STABILISED DESIGN, ACUVUE® OASYS 1-Day for ASTIGMATISM utilises four stabilisation zones with the lids to help keep the lens in place, even with eye or head movements, for consistent, clear and stable vision.1
  • Class 1 UV protection3†
    Tear-like molecules mimic the ocular mucins, lubricating and moisturising to help support a more stable tear-film2,4
    Coverage for 87% of astigmatic eyes5

HydraLuxe® Technology

A tear-infused design with an enhanced network of tear-like molecules and highly breathable hydrated silicone that integrates with the patient’s own tear film each day.2

EYELID STABILISED DESIGN

Designed to realign naturally with every blink and quickly orient and stabilise within minutes of insertion1, giving astigmatic patients the clear, stable vision1 they deserve.

  • No vertical prism in the optic zone1^
  • 95% orientate within 10 degrees from zero position after 3 minutes settling1

  • As easy to fit as the spherical lenses1+
  •  

Related Products

Packing solution contains boric acid and disodium tetraborate (sodium borate) to control the pH of the solution.

* Designed to support the functions of the tear film

$ Based on VA, vision, fit, orientation stability, comfort and handling

All ACUVUE® Brand Contact Lenses have Class 1 or Class 2 UV-blocking to help provide protection against transmission of harmful UV radiation to the cornea and into the eye. UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. UV transmission measured with -1.00D lens.

^ Vertical heterophoria possibly caused by prism dissociation due to the presence of induced optical prism is a relevant factor for practitioners to consider when fitting toric contact lenses for monocular astigmats or those requiring a mix of toric soft contact lens designs.9,10 Clinical studies have not been done to fully characterize the clinical effects of differences in base down prism among different contact lenses.

+ Based on high fit success rates, number of lenses required and time to fit lenses during ACUVUE® Brand for ASTIGMATISM clinical studies

REFERENCES:

1. JJV Data on file 2024, ACUVUE® Brand Contact Lenses for ASTIGMATISM overall fitting success, orientation position, rotational stability and vision performance

2. JJV Data on File 2021. HydraLuxe Technology Definition.

3. JJV Data on File 2022. Material Properties: 1-DAY ACUVUE® MOIST, 1-DAY ACUVUE® TruEye®, ACUVUE® OASYS 1-Day with HydraLuxe® Technology and ACUVUE® OASYS MAX 1-Day with TearStable Technology Brand Contact Lenses.

4. JJV Data on File 2018. Similarities between Mucin and Poly(N-Vinyl Pyrrolidone) (PVP).

5. JJV Data on file October 2023. Proportion astigmats accommodated with ACUVUE® Brand CLs for ASTIGMATISM.

6. JJV Data on File 2018. Design ACUVUE® VITA Brand Contact Lenses for ASTIGMATISM.

7. Straker, B, Hamada, W, Sulley, A, et al. Fitting performance and efficiency with a new silicone hydrogel daily disposable toric contact lens. Contact Lens Anterior Eye. 2018;41(S1):S57-S58. doi: 10.1016/j.clae.2018.03.049.

8. JJV Data on File 2016. ACUVUE® OASYS Brand Products Comparison.

9. Jackson D, Bedell HE. Vertical heterophoria and susceptibility to visually induced motion sickness. Strabismus. 2012,20(1):17-23.

10. duToit R, Ramke J, Brian G. Tolerance to prism induced by readymade spectacles: setting and using a standard. Optom Vis Sci. 2007,84(11):1053-1059.

IMPORTANT SAFETY INFORMATION

ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lenses, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For detailed product information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use available on the Johnson & Johnson website www.e-IFU.com

2024PP16567

Johnson & Johnson MedTech
© Johnson & Johnson and its affiliates 2025. All rights reserved. This site is published by Johnson & Johnson Medical Limited, which is solely responsible for its content. It is intended for use by Eye Care Professionals of United Kingdom and Ireland.
Third party trademarks used herein are trademarks of their respective owners.

Footer 2024PP17596
Vision Made Possible